Skip to main content
. 2021 Apr 19;16(4):e0250354. doi: 10.1371/journal.pone.0250354

Fig 3. Effects of HLp-nF1 on inflammation state in loperamide-induced constipation.

Fig 3

Eight-week-old rats were treated with loperamide along with 3.2 × 1010, 8 × 1010, and 1.6 × 1011 cells/mL HLp-nF1, and Dulcolax, individually. A single treatment with 1.6 × 1011 cells/mL HLp-nF1 or Dulcolax was used as the control. (A) Immunoblotting for anti-IL-6, IL-1β, TNF-α, PGE2, COX-2, and β-actin antibody was performed using the ileum samples. (B) The expression of these proteins were quantified. A t-test was used to determine the means of two groups (n = 4). *P< 0.05 vs. control group, #P< 0.05 vs. loperamide-treated group. Con, control group; Lop, loperamide-treated group; Dul, Dulcolax-treated group (0.75 mg/kg); HHL, treatment with 1.6 × 1011 cells/mL HLp-nF1; Lop+LHL, treatment with loperamide and 3.2 × 1010 cells/mL HLp-nF1; Lop+MHL, treatment with loperamide and 8 × 1010 cells/mL HLp-nF1; Lop+HHL, treatment with loperamide and 1.6 × 1011 cells/mL HLp-nF1; Lop+Dul treated group.